Status: Recruiting
A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)
To find out if the combination of HC-7366 and nivolumab (with or without ipilimumab) can help to control ccRCC. The
Participants needed: 35
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: M.D. Anderson Cancer CenterUpdated: Apr 2, 2026Locations: 1
Eligibility criteria
Ability to understand and the willingness to sign a written informed consent doc... [+30]
More than 3 prior lines of systemic therapy allowed [+5]